Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, March 10, 2023
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
Thu, March 9, 2023
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
[ Thu, Mar 09th 2023
] - WOPRAI
Douglas Tsao Maintained (VRDN) at Strong Buy with Increased Target to $40 on, Mar 9th, 2023
Douglas Tsao of HC Wainwright & Co., Maintained "Viridian Therapeutics, Inc." (VRDN) at Strong Buy with Increased Target from $35 to $40 on, Mar 9th, 2023.
Douglas has made no other calls on VRDN in the last 4 months.
There are 4 other peers that have a rating on VRDN. Out of the 4 peers that are also analyzing VRDN, 0 agree with Douglas's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Douglas
- Thomas Smith of "SVB Leerink" Maintained at Buy with Increased Target to $45 on, Monday, January 9th, 2023
- Serge Belanger of "Needham" Initiated at Strong Buy and Held Target at $45 on, Monday, December 19th, 2022
- Tiago Fauth of "Credit Suisse" Initiated at Buy and Held Target at $51 on, Friday, December 16th, 2022
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $46 on, Tuesday, November 15th, 2022
